News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


YM BioSciences Drug Is Given Orphan Status

Posted on: 12/01/2004

YM BioSciences Drug Is Given Orphan Status

Associated Press
11.30.2004, 09:06 AM

YM BioSciences Inc. on Tuesday said the Food and Drug Administration has given an orphan-drug designation to its experimental drug for treating patients with brain cancer.

Orphan-drug status gives Ontario, Canada-based YM a seven-year exclusivity period, potential tax breaks, possible funding and assistance with clinical trials while the company develops its drug, TheraCIM hR3, to treat a rare condition that affects fewer than 200,000 people in the United States.

TheraCIM, which has already been designated an orphan drug by European regulators, is currently undergoing two mid-stage trials in Europe and is expected to begin late-stage testing early next year.

YM said its European licensee, Oncoscience AG, anticipates launching a late-stage trial of TheraCIM in adults with glioma, or brain cancer, in early 2005.

The drug, a monoclonal antibody that targets the epidermal growth factor receptor, has been shown to double a patient's response to chemotherapy in mid-stage trials of patients with head and neck cancer, the company said

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557